$CRMD: Q3 Fungal Filing Update

CorMedix beats Q2 estimates on revenue growth; CEO confirms supplemental filing for fungal treatment by Q3.

Loading exclusive…

Key Points

Q2 EPS of $0.29 beat consensus $0.26 by 21%
CEO confirms supplemental filing for fungal treatment expected in Q3
Revenue growth supports commercial momentum
Stock sees best day in 10 months on earnings beat

What To Watch

Q3 supplemental filing submission date
FDA feedback timeline post-filing
Q3 revenue guidance update

Market Analysis

How the tape may move from the last update’s mark — not from the open, and not the session % already printed.

The earnings beat and clear Q3 regulatory catalyst provide a near-term upside bias for $CRMD. The market is likely to price in the probability of a successful fungal filing, driving further gains if execution remains on track.

Expected Move From Here -2.0% to +5.0% From last update, not from the open

Certainty 65%

Why

The 21% EPS beat and specific Q3 filing update reduce near-term uncertainty. However, small-cap biotechs remain volatile, and regulatory timelines can shift. The range reflects expected consolidation after the initial post-earnings pop, with upside potential if Q3 filing news is confirmed.

Related Sources

CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat — Stocktwits
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates — Zacks
CorMedix Q2 Earnings Call Highlights — MarketBeat
CorMedix: Q2 Earnings Snapshot — Wire
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update — GlobeNewswire
S&P Global Stock Jumps 1.7% as Ackman Targets AI Fears — GuruFocus.com
fourteen — Insider Monkey
Apple opens Advanced Manufacturing Center in Houston — Business Wire
A Look Back at IT Distribution & Solutions Stocks’ Q2 Earnings: Insight Enterprises (NASDAQ:NSIT) Vs The Rest Of The Pack — StockStory
TERREPOWER Culminates Its Brand Evolution with Tagline 'Reimagine What's Possible' — PR Newswire